十字架
发表于 2025-3-28 14:48:09
http://reply.papertrans.cn/71/7014/701395/701395_41.png
Junction
发表于 2025-3-28 20:05:21
Kenar D. Jhaveri,Abdulla K. SalahudeenCovers the pathophysiology and management of kidney diseases in cancer patients.Case based resource features the latest evidence and clinical approaches.Fills a significant knowledge gap for nephrolog
Esophagus
发表于 2025-3-29 00:56:03
http://reply.papertrans.cn/71/7014/701395/701395_43.png
Compatriot
发表于 2025-3-29 05:17:23
http://reply.papertrans.cn/71/7014/701395/701395_44.png
机构
发表于 2025-3-29 08:57:48
http://reply.papertrans.cn/71/7014/701395/701395_45.png
expdient
发表于 2025-3-29 12:33:14
Electrolyte Disorders in Cancer Patients,chapter describes the frequency of the most commonly observed electrolyte disorders in the oncology patient and delves into the unique cancer- or chemotherapy-related etiology of these clinical problems.
的染料
发表于 2025-3-29 19:05:28
Renal Cell Carcinoma and Chronic Kidney Disease,es that affect long-term mortality and morbidity. In this population, chronic kidney disease (CKD), due to both underlying conditions as well as loss of renal mass, has become a key determinant of long-term outcomes.
Assault
发表于 2025-3-29 20:48:29
http://reply.papertrans.cn/71/7014/701395/701395_48.png
平息
发表于 2025-3-30 01:11:58
Biological Cancer Therapies and the Kidney,KD) due to chemotherapy. Nephrologists need to be aware of the presentation, prevention, and treatment of toxicities associated with targeted therapies. This chapter will review the kidney toxicities of antiangiogenic therapies, of epidermal growth factor receptor (EGFR) inhibitors, and of other multi-targeted tyrosine kinase inhibitors (TKI).
宇宙你
发表于 2025-3-30 06:24:45
http://reply.papertrans.cn/71/7014/701395/701395_50.png